Conflict of Interest: Nothing to report.
Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation
Article first published online: 30 NOV 2013
© 2013 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 6, pages 1104–1106, June 2014
How to Cite
Pinto, N., Cipkala, D. A., Ladd, P. E., Pu, Y. and Cohn, S. L. (2014), Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation. Pediatr. Blood Cancer, 61: 1104–1106. doi: 10.1002/pbc.24889
- Issue published online: 16 APR 2014
- Article first published online: 30 NOV 2013
- Manuscript Accepted: 6 NOV 2013
- Manuscript Received: 10 AUG 2013
- intermediate-risk neuroblastoma;
- refractory disease
Patients <12 months with favorable biology, metastatic neuroblastoma have >90% overall survival following treatment with chemotherapy and surgery. We report two infants with favorable biology, stage 4 neuroblastoma with refractory disease after standard intermediate-risk chemotherapy and additional retrieval chemotherapy. One patient was treated with six additional cycles of isotretinoin and the other observed. Both remain clinically well with persistent disease but no evidence of tumor progression for 28 and 13 months following completion of cytotoxic treatment. Similar to residual tumor in primary sites, refractory metastatic disease may not portend a poor outcome in patients with favorable biology, intermediate-risk neuroblastoma. Pediatr Blood Cancer 2014;61:1104–1106. © 2013 Wiley Periodicals, Inc.